← 返回

中国专家共识:静脉注射免疫球蛋白在血液系统疾病中的应用

英文原题:Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.

查看英文原题

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.

PubMed 2025/04/01(内容时间) Front Med (Lausanne) Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

静脉注射免疫球蛋白(IVIG)最初用于治疗抗体缺陷患者,现已在临床实践中广泛应用,尤其是在血液系统和免疫系统疾病中,其在血液肿瘤化疗、细胞免疫治疗和造血干细胞移植(HSCT)中的应用越来越普遍。中国感染免疫与微生态研究转化协作组组织相关专家讨论并提出《静脉注射免疫球蛋白在血液系统疾病中应用的中国专家共识》,该共识基于IVIG在血液病中应用的研究进展制定,为规范IVIG在血液系统疾病中的使用提供了依据。

展开英文摘要原文

Intravenous immunoglobulin (IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common.

The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the "Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases," which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.

论文信息

作者
Guo Z、Zhu J、Wang J、Wang L、Tang F、Huang H、Xia Z、Liu L
第一作者单位
Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.China
通讯作者单位
Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.China
文献类型
综述
期刊
Frontiers in medicine2025
原文标识
PubMed 40236459 · DOI 10.3389/fmed.2025.1544025